BNP

What is BNP?

BNP (B-type Natriuretic Peptide, originally and somewhat misleadingly called brain natriuretic peptide because it was first isolated from porcine brain) is a 32-amino-acid endogenous polypeptide hormone secreted predominantly by ventricular cardiomyocytes in response to mechanical stretch and increased wall stress. The mature 32-aa BNP is cleaved from a 108-aa prohormone (proBNP); the cleavage simultaneously generates a 76-aa biologically inert N-terminal fragment (NT-proBNP) that circulates alongside active BNP and forms the basis of the second major commercial assay. Although the atria release atrial natriuretic peptide (ANP) tonically, ventricular BNP is the dominant natriuretic peptide in clinical heart failure because it rises proportionally to ventricular wall stress and circulates at concentrations that span several orders of magnitude across health and decompensation. BNP plays two distinct roles in modern medicine: as a circulating hormone with vasodilatory, natriuretic, and counter-regulatory neurohormonal effects (the basis for the synthetic BNP drug nesiritide, covered separately), and as the analyte in one of the most-ordered cardiac laboratory tests in the world. The BNP and NT-proBNP assays — validated in the early 2000s through trials like Breathing Not Properly and PRIDE — sit at the center of acute dyspnea evaluation in emergency departments, chronic heart failure risk stratification, and increasingly the diagnosis and prognosis of heart failure with preserved ejection fraction.

What BNP Is Investigated For

BNP testing is among the most-ordered cardiac laboratory studies globally, and the reason is the body of work that established its clinical role between 2001 and 2004. The Breathing Not Properly multinational study (Maisel et al., NEJM 2002) enrolled 1,586 patients presenting to emergency departments with acute dyspnea and showed that a single rapid BNP measurement at presentation discriminated heart failure from non-cardiac dyspnea with an area under the ROC curve of 0.91, with a cutoff of 100 pg/mL providing 90% sensitivity and 76% specificity. Mueller and colleagues (NEJM 2004) then randomized acute-dyspnea patients to BNP-guided versus standard evaluation and showed the assay reduced time to discharge, hospital length of stay, and total treatment costs without compromising 30-day outcomes. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study (Januzzi et al., Am J Cardiol 2005) extended the same diagnostic case to NT-proBNP, with age-stratified cutoffs (450/900/1800 pg/mL for under 50, 50–75, and over 75) that remain in widespread use. Beyond acute diagnosis, both peptides have been validated as powerful prognostic markers — higher concentrations track with worse outcomes across HFrEF, HFpEF, acute coronary syndromes, pulmonary embolism, and pulmonary hypertension. The promise of using serial natriuretic peptides to titrate heart failure therapy has been more equivocal: the GUIDE-IT trial (Felker et al., JAMA 2017) randomized 894 high-risk HFrEF patients to NT-proBNP-guided versus usual GDMT and found no improvement in hospitalization or cardiovascular mortality, ending the trial early for futility. Contemporary guidelines from the AHA/ACC/HFSA (2022) and ESC (2021) endorse BNP and NT-proBNP for diagnosis, risk stratification, and prognosis but stop short of recommending serial-measurement-guided dose titration as a routine strategy. The introduction of sacubitril/valsartan (an angiotensin receptor-neprilysin inhibitor, ARNi) added a new wrinkle: by inhibiting neprilysin (the enzyme that degrades BNP), ARNi raises BNP concentrations even as it improves outcomes, while NT-proBNP — which is not a neprilysin substrate — falls. This is why NT-proBNP has become the preferred analyte for monitoring patients on sacubitril/valsartan therapy.

History & Discovery

BNP was discovered in 1988 by Tetsuji Sudoh, Kenji Kangawa, Naoto Minamino, and Hisayuki Matsuo at the National Cardiovascular Center Research Institute and Miyazaki Medical College in Japan. Their seminal Nature paper (Sudoh et al., Nature 332:78–81) reported the isolation of a 26-amino-acid peptide from porcine brain that exhibited natriuretic activity distinct from atrial natriuretic peptide (ANP), which Kangawa and Matsuo had themselves identified four years earlier in 1984. They named the new peptide 'brain natriuretic peptide' to reflect its tissue of isolation, and the name stuck — even after subsequent work showed that the peptide was overwhelmingly produced by ventricular cardiomyocytes rather than neurons. The 'B' in BNP today is generally read as 'B-type' to acknowledge the corrected tissue origin while preserving the original abbreviation. The initial porcine sequence was rapidly extended to humans, and the cloning of the human NPPB gene allowed identification of the 32-amino-acid mature human BNP and the 108-amino-acid proBNP precursor. Through the late 1980s and 1990s, work by Yoshibayashi, Mukoyama, Yasue, Burnett, and others established that BNP was secreted predominantly by ventricular myocardium in response to wall stretch, that circulating concentrations rose dramatically in heart failure and acute coronary syndromes, and that the natriuretic peptide receptor A (NPR-A, guanylyl cyclase-A) was the principal signaling receptor mediating the peptide's vasodilatory and natriuretic effects. The N-terminal pro-fragment NT-proBNP was characterized as an inactive but stable circulating co-product — initially seen as a curiosity but later recognized as a uniquely useful analyte because of its longer half-life and renal clearance. The transition from research peptide to clinical biomarker accelerated in the late 1990s with the development of commercial immunoassays for both BNP (introduced by Biosite as the Triage BNP assay, FDA-cleared in 2000) and NT-proBNP (Roche Elecsys assay). The pivotal validation came in the early 2000s. Dao et al. (J Am Coll Cardiol 2001) showed BNP could distinguish heart failure from non-cardiac dyspnea in an urgent-care setting. The Breathing Not Properly multinational study (Maisel et al., NEJM 2002) extended this to a 1,586-patient ED cohort and provided the diagnostic performance benchmark that drove guideline incorporation. Mueller et al. (NEJM 2004) demonstrated that BNP-guided ED evaluation reduced cost and length of stay. Januzzi and the PRIDE investigators (Am J Cardiol 2005) established analogous diagnostic performance for NT-proBNP with age-stratified cutoffs. The parallel therapeutic story is that synthetic BNP — the recombinant 32-amino-acid peptide nesiritide (Natrecor) — was approved by the FDA in August 2001 for acute decompensated heart failure based on the VMAC trial. Nesiritide had a controversial commercial and clinical trajectory: post-marketing concerns about renal injury and mortality (Sackner-Bernstein meta-analyses 2005), the larger ASCEND-HF trial (O'Connor et al., NEJM 2011) which showed no clinical benefit, and effective withdrawal from clinical practice. Nesiritide is covered separately on this site. The last major chapter in BNP biology has been the rise of the angiotensin receptor-neprilysin inhibitor class. Sacubitril/valsartan (Entresto), approved in 2015 based on the PARADIGM-HF trial, inhibits the neprilysin enzyme that degrades active BNP and several other peptides, thereby potentiating endogenous natriuretic peptide signaling. The drug substantially reduced cardiovascular mortality in HFrEF, vindicating decades of work on the natriuretic peptide axis as a therapeutic target. The biomarker consequence — active BNP rises on neprilysin inhibition while NT-proBNP falls — has become a critical practical point in modern heart failure management and reshaped lab-monitoring practice. NT-proBNP, once seen as a junior analyte to active BNP, is now arguably the more clinically useful of the two in the ARNi era.

How It Works

Your heart's lower chambers (the ventricles) constantly sense how stretched their walls are. When pressure or volume inside the heart rises — as happens in heart failure — the ventricular muscle cells release a peptide hormone called BNP into the bloodstream. BNP travels to the kidneys and blood vessels and tells them to dump salt and water and to relax — the body's built-in attempt to relieve the overload. Because the amount of BNP in the blood scales with how stretched the heart is, doctors can measure it as a chemical readout of cardiac stress. The blood test is one of the most-ordered cardiac labs in the world, used in emergency rooms to figure out whether shortness of breath is coming from the heart and in clinics to track how a patient with heart failure is doing.

BNP is encoded by the NPPB gene on chromosome 1p36.2 and is synthesized as a 134-amino-acid pre-prohormone. After signal peptide cleavage, the 108-amino-acid proBNP is processed by the proprotein convertases corin and furin into two circulating fragments: the biologically active 32-amino-acid BNP (the C-terminal portion) and the inactive 76-amino-acid NT-proBNP. Both fragments are released into the circulation in equimolar quantities, but their pharmacokinetics diverge sharply. The primary stimulus for BNP synthesis and release is ventricular wall stretch — increased end-diastolic pressure, end-systolic volume, or wall tension all upregulate NPPB transcription within minutes to hours. Unlike ANP, which is stored in atrial granules and released by exocytosis, ventricular BNP is largely a regulated-secretion product synthesized on demand, which is why its plasma concentration tracks current hemodynamic loading rather than long-term cardiac structural status. Additional stimuli include angiotensin II, endothelin-1, sympathetic activation, hypoxia, and inflammatory cytokines such as IL-1β and TNF-α. Active BNP exerts its effects by binding natriuretic peptide receptor A (NPR-A, also called guanylyl cyclase-A or GC-A), a single-transmembrane receptor with intrinsic guanylyl cyclase activity. Ligand binding activates the intracellular cyclase domain, generating cyclic GMP from GTP. Downstream cGMP signaling (via cGMP-dependent protein kinase G, cGMP-gated ion channels, and cGMP-regulated phosphodiesterases) produces the canonical natriuretic peptide effects: arterial and venous vasodilation (reducing preload and afterload), natriuresis and diuresis at the level of the renal collecting duct and inner medullary collecting duct, suppression of renin and aldosterone secretion, antagonism of sympathetic tone, and antifibrotic and antihypertrophic effects on cardiac myocytes and fibroblasts. The natriuretic peptide system is thus a counter-regulatory axis to the renin-angiotensin-aldosterone and sympathetic systems. Clearance of active BNP occurs by two mechanisms. The first is receptor-mediated internalization and degradation by natriuretic peptide receptor C (NPR-C), a clearance receptor that binds all natriuretic peptides without activating cGMP. The second is enzymatic degradation by neprilysin (membrane metalloendopeptidase, NEP), a zinc-dependent ectoenzyme abundant on renal tubular brush borders, vascular endothelium, and other tissues. Neprilysin cleaves active BNP and other natriuretic peptides as well as bradykinin, substance P, and adrenomedullin. Plasma half-life of active BNP is roughly 20 minutes. NT-proBNP, by contrast, is not a neprilysin substrate and is cleared primarily by the kidneys with a longer half-life of 60–120 minutes. Because of this difference, NT-proBNP concentrations are typically 5–10 times higher than active BNP at any given level of cardiac stress. NT-proBNP is more sensitive to renal function — values rise as eGFR declines independent of cardiac status — and concentrations are elevated in older patients and in atrial fibrillation. The molecular basis of NT-proBNP's longer half-life and resistance to neprilysin makes it the preferred analyte for monitoring patients on the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan, which inhibits neprilysin and thus raises active BNP independent of any change in cardiac status, while NT-proBNP — being neprilysin-independent — accurately reflects underlying cardiac improvement on therapy. The diagnostic and prognostic utility of BNP and NT-proBNP arises from the steep concentration-response relationship between ventricular wall stress and natriuretic peptide secretion. In healthy individuals, BNP is typically <20 pg/mL and NT-proBNP is <50–75 pg/mL. In acute decompensated heart failure, concentrations can rise 50- to 500-fold. The Breathing Not Properly study established that BNP discriminates cardiogenic from non-cardiogenic dyspnea in the ED with an AUC of 0.91; PRIDE established analogous performance for NT-proBNP with age-stratified cutoffs; subsequent studies extended the prognostic utility to chronic heart failure, ACS, pulmonary embolism, and pulmonary hypertension. The natriuretic peptide system is also the therapeutic target of the synthetic BNP drug nesiritide and, indirectly, of sacubitril/valsartan, which potentiates endogenous BNP signaling by blocking its degradation.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about BNP:

• 01Optimal natriuretic peptide cutoffs for HFpEF diagnosis and monitoring are still imperfectly defined — values are generally lower in HFpEF than HFrEF for any given symptom severity, and obese HFpEF patients can have values below conventional cutoffs even with hemodynamically significant disease.
• 02The negative GUIDE-IT result largely closed the door on routine NT-proBNP-guided therapy for chronic stable HFrEF, but specific subpopulations (younger patients, those with persistently elevated values despite optimized GDMT, transplant evaluation) may still benefit from biomarker-guided intensification — the boundaries of this remain unclear.
• 03Multimarker risk-stratification approaches combining natriuretic peptides with high-sensitivity troponin, soluble ST2, galectin-3, and emerging proteomic panels have shown incremental prognostic value but have not produced a single dominant clinical algorithm.
• 04The interpretation of natriuretic peptides in obese patients — where adipose-related factors lower circulating concentrations — has not been resolved into widely accepted cutoff adjustments, and patients with BMI >35 are an under-represented group in the foundational validation studies.
• 05Pediatric and congenital heart disease cutoffs are less well established than adult cutoffs and depend heavily on age, lesion type, and surgical history.
• 06The role of natriuretic peptides as treatment-response markers for newer agents (SGLT2 inhibitors, vericiguat, omecamtiv mecarbil) has been characterized in trials but has not been integrated into routine monitoring algorithms.
• 07The biology of NT-proBNP processing, glycosylation, and immunoassay cross-reactivity has been refined over the last decade, but inter-assay differences across vendors continue to complicate threshold harmonization in research and clinical pathways.

Forms & Administration

Endogenous BNP is not administered — it is produced by ventricular cardiomyocytes and circulates in the plasma as the body's own counter-regulatory hormone. The clinical 'use' of BNP in routine medicine is as an analyte measured from a standard venous blood draw using one of two commercial assay families: the BNP assay (which measures active 32-amino-acid BNP, typically by sandwich immunoassay) and the NT-proBNP assay (which measures the inactive N-terminal fragment). Both are widely available on hospital chemistry analyzers and at most major reference laboratories, with point-of-care options available for emergency-department use. Results are typically reported in pg/mL, with assay-specific cutoffs and age stratification (particularly for NT-proBNP). For therapeutic use of synthetic BNP — the recombinant peptide nesiritide (Natrecor) — see the dedicated nesiritide entry; nesiritide is administered intravenously in a hospital setting, has a complex regulatory and clinical history, and is now used rarely in contemporary practice.

Common Questions

Who BNP Is NOT For

Drug & Supplement Interactions

Endogenous BNP itself does not have 'drug interactions' in the conventional sense — it is a physiologic hormone whose plasma concentration is influenced by underlying cardiac, renal, and pulmonary status rather than by drug pharmacokinetics. The clinically important interaction concerns BNP and NT-proBNP as biomarkers, where several drug classes alter their measured concentrations and thus their interpretation. The most important is the angiotensin receptor-neprilysin inhibitor (ARNi) class — sacubitril/valsartan (Entresto). Sacubitril is metabolized to sacubitrilat, which inhibits neprilysin, the metalloendopeptidase that degrades active BNP. The result is that on ARNi therapy, circulating BNP rises (because clearance is slowed) even when the patient's underlying heart failure is improving. NT-proBNP, which is not a neprilysin substrate, falls with effective therapy as a true marker of clinical improvement. This divergence is why guidelines and most clinicians prefer NT-proBNP over BNP for serial monitoring in patients on sacubitril/valsartan. Beta-blockers, ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, SGLT2 inhibitors, and loop diuretics — the components of guideline-directed medical therapy — generally lower both BNP and NT-proBNP concentrations as they reduce ventricular wall stress through hemodynamic improvement. This effect is desirable and reflects underlying clinical benefit, but means that biomarker concentrations should be interpreted relative to the patient's prior values and current therapy regimen rather than against absolute population cutoffs. Mechanical circulatory support (LVADs) typically reduces BNP and NT-proBNP after device optimization but with substantial individual variability. Medications and conditions that cause renal impairment (NSAIDs, contrast nephropathy, ACE inhibitor over-titration in volume-depleted patients) raise NT-proBNP through reduced renal clearance and complicate interpretation, particularly when eGFR falls below 60 mL/min/1.73m². Corticosteroids, thyroid hormone replacement, and adrenergic agonists can transiently affect natriuretic peptide concentrations through hemodynamic mechanisms, but the effect is generally not large enough to change clinical interpretation in most contexts.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions